Nucleic acid encoding bone marrow stromal antigen 1 antibody

• US 10,239,956 B2
• Filed: 07/10/2017
• Issued: 03/26/2019
• Est. Priority Date: 06/28/2011
• Status: Active Grant

• Current Assignee: Oxford BioTherapeutics LTD
• Original Assignee: Oxford BioTherapeutics LTD
• Inventors: Rohlff, Christian, Terrett, Jonathan Alexander
• Primary Examiner(s): Mertz, Prema M
• Application Number:
  US15/645,041
• Publication Number:
  US 20170313785A1
• Time in Patent Office: 624 Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 47/6871 the antibody targeting an enzyme
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 16/40 against enzymes
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/30 characterized by aspects of specificity or valency
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/77 Internalization into the cell

Abstract

The invention provides antibodies which bind to the ADP-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of human cancers, including acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer and pancreatic cancer and human inflammatory diseases, including asthma, gout, crohns, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, diabetes and atherosclerotic.

Claims

1. An isolated nucleic acid comprising a nucleotide sequence encoding an antibody variable region, wherein the antibody variable region comprises SEQ ID NO:

2, SEQ ID NO;

4, SEQ ID NO;

46, or SEQ ID NO;

49.

2. The isolated nucleic acid of claim 1, wherein the antibody variable region comprises SEQ ID NO:

2.

3. The isolated nucleic acid of claim 1, wherein the antibody variable region comprises SEQ ID NO:

4.

4. The isolated nucleic acid of claim 1, wherein the antibody variable region comprises SEQ ID NO:

46.

5. The isolated nucleic acid of claim 1, wherein the antibody variable region comprises SEQ ID NO:

49.

9. An isolated host cell containing the nucleic acid of claim 1.

11. A method of making an antibody comprising culturing a host cell according to claim 9 under conditions where an antibody, or antigen binding portion thereof, is expressed and isolating the antibody, or antigen binding portion thereof.

6. An isolated nucleic acid comprising a nucleotide sequence comprising SEQ ID NO:

6, or SEQ ID NO;

8.

7. The isolated nucleic acid of claim 6, wherein the nucleotide sequence comprises SEQ ID NO:

6.

8. The isolated nucleic acid of claim 6, wherein the nucleotide sequence comprises SEQ ID NO:

8.

10. An isolated host cell containing the nucleic acid of claim 6.

12. A method of making an antibody comprising culturing a host cell according to claim 10 under conditions where an antibody, or antigen binding portion thereof, is expressed and isolating the antibody, or antigen binding portion thereof.